These 2 FTSE 100 growth stocks I like are climbing while markets crash

Not every stock on the FTSE 100 (INDEXFTSE:UKX) is falling today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Everywhere you look, FTSE 100 stocks are crashing. Travel operator TUI AG is down 40% over the last month. Cruise operator Carnival is down 30%. Overall, the FTSE 100 is down around 15%. Yet not every company is having a rough time of it. 

Two of the best performers of recent years are defying the downturn and have continued to grow over the last month. Now could be a good time to check out the Hikma Pharmaceuticals (LSE: HIK) and Rentokil Initial (LSE: RTO) share prices, which are staying afloat, as almost every other company sinks along with the market.

Pharmaceutical stocks tend to hold their own when stock markets are falling, because people continue to fall ill in a recession, often more than before. 

Hikma Pharmaceuticals

This is particularly true now, as markets fall due to the coronavirus global health scare. Hikma stock is up around 5% over the last week, at time of writing. Over two years, it’s up 124%.

Hikma was given a timely lift by a positive set of preliminaries last week, which showed group core revenue up 6%, with group operating profit surging 33% to $493m. It also strengthened its balance sheet by trimming net debt to $242m, while raising his full-year dividend more than 15% to 44 cents per share.

Many investors overlook Hikma as they target pharma big guns AstraZeneca and GlaxoSmithKline. But this £4.72bn stock has huge growth potential, launching 108 new products across all its global markets last year, and signing 18 licensing agreements for the US and MENA. Its flowing pipeline should help drive future revenues.

Hikma shares should also benefit from its recent blockbuster agreement with Glenmark Pharmaceuticals. Some pharmaceutical stocks have soared on speculation about developing new coronavirus treatments, leaving them overbought.

But that isn’t the driver here. Hikma is just a very good company on a roll. Yet it trades at a modest valuation of 14.5 times forward earnings, while its 1.8% yield is covered 3.7 times by earnings, giving plenty of scope for growth. I’d buy it for the long-term.

Rentokil Initial

Rentokil Initial is also up around 5% over the past week, and a bumper 100% over two years, during which time the FTSE 100 as a whole actually fell 7.5%.

The £9.59bn group is a direct beneficiary of current worries because, along with its renowned pest control services, it also supplies hand washing and hand sanitising services. Again though, this is far from a pure coronavirus play. Last week, the Rentokil share price flew as it posted a 10% increase in adjusted pre-tax profits to £341m, with organic revenue growth of 4% — its highest level in 15 years.

This is a global business, and is performing strongly in its Pacific business region, as countries urbanise and pest control becomes more important, as well as in the UK and Europe.

The big concern is that, after recent share price success, Rentokil stock looks pricey. It trades at 31.8 times forecast earnings, while the yield is relatively low at 1.4%, despite progressive management that recently hiked payouts by 15.2%.

I’d prefer a more reasonable valuation, but this stock is in demand right now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »